Nasal corticosteroid treatment reduces substance P levels in tear fluid in allergic rhinoconjunctivitis

What Was Tested

Researchers studied Substance P in this controlled clinical trial publication.

To study the effects of nasal fluticasone furoate (FF) on conjunctival symptoms and substance P and histamine levels in tear fluid after nasal grass pollen provocation (GPP).

Why It Was Studied

A naso-ocular reflex may be present.

Who Took Part

The age groups tagged for this paper are young adults and adults, both men and women.

A double-blind placebo-controlled study was performed in 26 grass pollen-allergic patients.

A selective GPP was performed during the grass pollen season after 2 weeks of FF or placebo treatment.

How the Study Was Run

The design is described as double-blind and placebo-controlled.

Blinding on both sides kept the participants and researchers unaware of who received Substance P.

Some participants received a placebo instead of Substance P, giving a reference point.

The methods mention a period of 2 weeks.

Nasal and conjunctival symptoms were scored using a visual analog scale (VAS), and tear fluid was collected for measuring substance P and histamine using an enzyme-linked immunosorbent assay.

What Was Measured

Topics PubMed links to this paper include Adrenal Cortex Hormones, Androstadienes, Antigens, Plant, Conjunctiva, Conjunctivitis, Allergic, Histamine and Nasal Provocation Tests.

What This Means in Plain Language

The paper is a double-blind and placebo-controlled study of Substance P over 2 weeks.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2012 (Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology), a journal based in United States.

More context: the Substance P compound page, all human trials.